Zydus Gets First Canada Nod for Drug

  Published 8 months ago

Zydus received its first NOC from Health Canada for ZDS-Varenicline, aiding smoking cessation, with production in Ahmedabad.

  • ZDS-Varenicline (0.5 & 1 mg) targets smoking addiction by partially activating nicotinic acetylcholine receptors in the brain.
  • Tablets to be manufactured at Zydus Lifescience SEZ unit in Ahmedabad, marking a milestone for the group in Canada.
  • Varenicline tablets saw annual sales of CAD 15 million in Canada as of December 2024 (IQVIA MAT).
You might like these

Alibaba's Taobao Instant Commerce Booms

Sun Pharma Research Shares Fall 15% After Trial Failure

Sensex Sheds 586 pts as Tariffs Bite

McDonald's India Launches Protein Slice

Reliance Defence Secures 600 Crore Export Order

JK Tyre’s Strong Q2 Surge

Schaeffler India Q2 Profit Up 12%

News that matters the most ⚡